Genetic Testing Access Programs

Through our partnership with Chiesi Global Rare Diseases, eligible patients with suspected Alpha-Mannosidosis can receive no-cost genetic testing to help confirm diagnosis and guide appropriate clinical care.

Through our Autism Partnership Program, SHANK3 Autism Anwers, eligible patients who meet eight clinical criteria can receive guideline-backed exome testing with financial support.

Many insurance companies recognize the importance of exome sequencing for patients with unexplained epilepsy, and their coverage policies reflect that understanding. Our Epilepsy Answers Program provides even greater access to exome testing for eligible patients with epilepsy.

Through our partnership with Chiesi Global Rare Diseases, eligible patients with suspected Fabry disease can receive no-cost genetic testing to support timely diagnosis and guide appropriate clinical care.

Through our partnership with Zevra Therapeutics, eligible patients with suspected Niemann-Pick disease type C (NPC) can receive no-cost genetic testing to support timely diagnosis and guide appropriate clinical care

Through our partnership with Beren Therapeutics P.B.C., eligible patients with suspected Niemann-Pick disease Type C (NPC) may receive no-cost whole genome sequencing to support earlier diagnosis and informed clinical care.

BioMarin in partnership with GeneDx is offering a no cost genetic testing program for infants with suspected Generalized Arterial Calcification of Infancy (GACI) due to ENPP1 Deficiency (GACI Type 1) or ABCC6 Deficiency (GACI Type 2). Through this program, your eligible patients can receive ultraRapid genome sequencing (uRGS) for free.